Cinaciguat, a Soluble Guanylate Cyclase Activator: Results from the Randomized, Controlled, Phase IIb COMPOSE Programme in Acute Heart Failure Syndromes
Mihai Gheorghiade(Northwestern University), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Gerasimos Filippatos(National and Kapodistrian University of Athens), Erland Erdmann(University of Cologne), Christina Nowack(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Aldo P. Maggioni(Health Care Foundation), Phillip D. Levy(Wayne State University), Roberto Ferrari(University of Ferrara), Stephen J. Greene(Duke Medical Center)
Cited by 123
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k